Digital CNS Platform P1vital offers an integrated eCOA platform with neuropsychology-based technology and validated objective measures, enabling a one-stop solution across all phases of CNS trials, which can be leveraged to consolidate vendors and reduce trial complexity for prospective clients.

Validated Assessments The Facial Expression Recognition Task is a clinically validated measure used in over 45 trials, providing a differentiator for objective behavioral and cognitive endpoints that can enhance data quality and trial endpoints for neuropsychiatric programs.

Strategic Partnerships Recent collaboration with University of Oxford researchers on Depression Treatment prediction studies and the Oxford NA partnership indicate opportunities to co-develop or expand digital biomarkers, appealing to sponsors seeking strong academic collaborations.

SMB Focused Upsell With a current revenue under $1M and a funded runway of $4.7M, P1vital presents a scalable opportunity for mid-market sponsors seeking cost-efficient, end-to-end digital trial solutions in CNS, potentially capturing share from larger multi-vendor platforms.

Global Trials Readiness The platform's applicability across all phases and ability to deploy beyond CNS to other therapeutic areas positions P1vital as a flexible partner for sponsors running multi-therapy portfolios or global trials requiring standardized digital endpoints.